FY2025 EPS Estimates for uniQure Cut by Cantor Fitzgerald

uniQure N.V. (NASDAQ:QURE) – Research analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for shares of uniQure in a research note issued to investors on Tuesday, November 11th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology company will post earnings per share of ($3.74) for the year, down from their prior estimate of ($3.33). Cantor Fitzgerald has a “Overweight” rating and a $80.00 price objective on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share. Cantor Fitzgerald also issued estimates for uniQure’s FY2026 earnings at ($3.52) EPS.

A number of other research firms have also commented on QURE. Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a report on Saturday, August 2nd. HC Wainwright dropped their price objective on uniQure from $110.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, November 4th. Stifel Nicolaus boosted their target price on uniQure from $30.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Benchmark restated a “buy” rating on shares of uniQure in a research note on Tuesday, November 4th. Finally, Leerink Partners reduced their price target on shares of uniQure from $68.00 to $60.00 and set an “outperform” rating for the company in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $64.42.

uniQure Stock Performance

QURE stock opened at $30.12 on Thursday. The stock has a market capitalization of $1.65 billion, a PE ratio of -7.68 and a beta of 0.59. uniQure has a 12-month low of $5.50 and a 12-month high of $71.50. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. The stock’s 50 day simple moving average is $42.80 and its 200 day simple moving average is $24.54.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). The firm had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $4.46 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%.

Insider Transactions at uniQure

In other news, Director Robert Gut sold 31,434 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $27.26, for a total value of $856,890.84. Following the transaction, the director owned 40,145 shares in the company, valued at $1,094,352.70. This represents a 43.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jack Kaye sold 38,810 shares of the firm’s stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $30.34, for a total transaction of $1,177,495.40. Following the completion of the transaction, the director directly owned 20,439 shares in the company, valued at approximately $620,119.26. The trade was a 65.50% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 314,560 shares of company stock valued at $12,362,568. Company insiders own 4.79% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in QURE. Vestal Point Capital LP boosted its stake in shares of uniQure by 58.4% during the 1st quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company’s stock worth $50,801,000 after acquiring an additional 1,767,572 shares during the last quarter. Aberdeen Group plc increased its stake in shares of uniQure by 6.9% in the 3rd quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock worth $171,593,000 after purchasing an additional 189,029 shares in the last quarter. Nantahala Capital Management LLC raised its holdings in uniQure by 3.8% in the 1st quarter. Nantahala Capital Management LLC now owns 2,755,962 shares of the biotechnology company’s stock worth $29,213,000 after purchasing an additional 101,598 shares during the period. Jefferies Financial Group Inc. purchased a new position in uniQure during the second quarter valued at $29,217,000. Finally, JPMorgan Chase & Co. lifted its position in uniQure by 471.7% during the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock valued at $25,199,000 after purchasing an additional 1,491,486 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.